Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Bristol Myers Squibb and Exelixis
Renal cell carcinoma (RCC) is a kidney cancer that originates in the
lining of the proximal convoluted tubule, a part of the very small
tubes in the kidney that transport waste molecules from the blood to
the urine. RCC is the most common type of kidney cancer in adults,
responsible for approximately 90–95% of cases. In 2021, it is
estimated that there will be approximately 76,080 new cases of
kidney cancer, and about 13,780 people will die from the disease.
Approximately 16% of patients with RCC will have metastases at
diagnosis, and as many as 40% will demonstrate metastasis after
primary surgical treatment for localized RCC. With a 5-year survival
rate ranging from 5% to 12%, the prognosis for these patients is
poor. Fortunately for patients with advanced RCC, many new
treatments have recently become available or have completed clinical
trials, especially in the area of immunotherapy combinations, giving
clinicians new options to improve patient outcomes and quality of
life. With so many new options becoming available for the healthcare
community, clinicians and medical directors are struggling to stay
abreast of all the changes in advanced RCC treatment, especially in
the evolving area of immunotherapy and targeted therapy
combinations. The prognosis for any treated renal cell cancer
patient with progressing, recurring, or relapsing disease is poor,
regardless of cell type or stage. Almost all patients with advanced
renal cell cancer are incurable. The question and selection of
further treatment depends on many factors, including if there has
been any previous treatment and site of recurrence, as well as
individual patient considerations. Fortunately, clinicians are being
equipped with immune checkpoint inhibitors, both alone and in
combination with targeted therapies, to integrate into the advanced
RCC treatment paradigm, which individualize therapy for patients
with advanced RCC, ultimately improving patient outcomes and quality
of life. These new options, some of which have been approved in
recent months, have shown improved efficacy and safety in advanced
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of advanced renal cell carcinoma (RCC), including factors
that contribute to poor prognosis and increased costs
Evaluate recent clinical data
regarding mechanistic activity, efficacy, and safety of new and
emerging immunotherapies and targeted therapies, including their
combination, for advanced RCC
Explore the evolving role of
immunotherapy and targeted therapy combinations in the
first-line management of advanced RCC
Assess strategies to optimally
sequence immunotherapy combinations in advanced RCC management
Review strategies to monitor and
manage adverse events associated with immunotherapy and targeted
therapy combinations in advanced RCC in order to improve patient
adherence and quality of life
Discuss the managed care
considerations of current and emerging immunotherapy and
targeted therapy combinations by exploring where these agents
fit into the current advanced RCC management paradigm
||Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Choueiri serves on an advisory board and as a consultant
for AstraZeneca, Aveo, Bayer, Eisai, Bristol Myers
Squibb, EMD Serono, Exelixis, Lilly, Merck & Co.,
Novartis Pharmaceuticals Corporation, Roche, Sanofi,
Takeda, Tempest, and Pfizer. He has received
grant/research support from Bristol-Myers Squibb,
Exelixis, and GlaxoSmithKline. His presentation has been
peer reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Bristol Myers Squibb and Exelixis
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue